ZNF384-related fusion genes consist of a subgroup with a characteristic immunophenotype in childhood B-cell precursor acute lymphoblastic leukemia


Disclosures: 1. This work was supported in part by a Health and Labour Sciences Research Grant (3rd-term comprehensive 10-year strategy for cancer control H22-011), the Grant of the National Center for Child Health and Development (26-20), and the Advanced Research for Medical Products Mining Programme of the National Institute of Biomedical Innovation (NIBIO, 10-41, -42, -43, -44, -45), and Biobank Japan project funded by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Agency for Medical Research and Development (AMED), and the Practical Research for Innovative Cancer Control from AMED. These funding sources played no role in the collection, analysis, or interpretation of the results, or in the writing of the manuscript and decision to submit it. 2. The authors had no financial relationships with commercial entities. 3. EP300-ZNF384 is patent pending in Japan and other countries as a new diagnostic procedure by NK, KM, and HI.